With worldwide spending on prescription drugs increasing from an estimated $774B in 2017 to over $1 trillion in 2022, a rising tide of pharmaceutical sales is lifting a lot of drug company boats and creating plenty of opportunities for investors.
With worldwide spending on prescription drugs increasing from an estimated $774 billion in 2017 to over $1 trillion in 2022, a rising tide of pharmaceutical sales is lifting a lot of drug company boats and creating plenty of opportunities for investors. Much of the profit from this boom will accrue to riskier, entrepreneurial enterprises specializing in a particular new approach, but among the big pharma companies that conservative investors value for their stability, diversification, and cash generation, there will be relative winners and losers.
